Acelrx Pharmaceuticals (ACRX) 6.61 $ACRX
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BIRT: 6.60 (+0.02), ACRX: 6.61 (+0.06), AWR: 37.12 (+0.53), ACPW: 1.87 (+0.02), ADUS: 23.80 (-0.19)
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 6.61 (+0.06), XNCR: 16.83 (+0.77)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), INFI: 16.65 (+0.37), IG: 9.11 (-0.01)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
ACRX: 6.61 (+0.06), CSCD: 14.28 (-0.21), BGFV: 14.46 (-0.12), BAH: 27.08 (-0.03), ACCO: 9.12 (+0.13)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), LJPC: 16.35 (-0.10), IG: 9.11 (-0.01)
Sedation - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxkbln/sedation) has announced the addition of the "Sedation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - AcelRx Pharmaceuticals - Paion - Maruishi Pharmaceutical - NanoMedex Pharmaceuticals - Advicenne Pharma For more information visit http://www.researchandmarkets.com/research/fxkbln/sedation
ACRX: 6.61 (+0.06)
Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:31AM CST
AcelRx Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
PR Newswire - Tue Dec 02, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. Zalviso is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. AcelRx has partnered with the Grunenthal Group to commercialize Zalviso in the European Union and Australia. AcelRx had previously announced that in July 2014, Grunenthal had submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for Zalviso for the management of moderate to severe acute pain in adult patients in a medically supervised environment. Obtaining the CE Mark is an important step in the potential approval of the Zalviso MAA.
ACRX: 6.61 (+0.06)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.61 (+0.06), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11), SRNE: 9.50 (+0.99), NEPT: 1.88 (+0.03), CELG: 109.60 (+3.48)
EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX
GlobeNewswire - Fri Nov 21, 5:47PM CST
Rosen Law Firm, P.A. reminds purchasers of common stock and call options and sellers of put options of AcelRx Pharmaceuticals, Inc. (Nasdaq:ACRX) during the period from December 2, 2013 through September 25, 2014 of the important December 1, 2014 lead plaintiff deadline in the class action.
ACRX: 6.61 (+0.06)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX
GlobeNewswire - Thu Nov 20, 10:58AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRX's put options between December 2, 2013 and September 25, 2014.
ACRX: 6.61 (+0.06)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
Business Wire - Thu Nov 20, 9:32AM CST
Law Offices of Howard G. Smith reminds investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company" (NASDAQ:ACRX) that those who purchased or otherwise acquired AcelRx's common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" , have until December 1, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events
PR Newswire - Thu Nov 20, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at Piper Jaffray, RBC, Guggenheim and Roth Healthcare Conferences. Details of the events are as follows:
ACRX: 6.61 (+0.06)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Nov 19, 8:42PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company" (NASDAQ: ACRX) common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 1, 2014 to seek appointment as lead plaintiff.
ACRX: 6.61 (+0.06)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014
Business Wire - Mon Nov 17, 5:48PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company" (Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRX's put options between December 2, 2013 and September 25, 2014.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals Announces Zalviso(TM) Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting
PR Newswire - Thu Nov 13, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that a moderated poster presentation will be made at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 13th Annual Pain Medicine Meeting to be held November 13th to November 16th, 2014 at the Hyatt Regency in San Francisco, CA. The annual ASRA meeting is the foremost scientific and educational event on invasive and non-invasive targeted therapies in pain medicine and brings together over 900 national and international thought leaders. Pamela Palmer, M.D. Ph.D. will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold
at The Street - Wed Nov 12, 8:04AM CST
AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
at The Street - Tue Nov 11, 11:00AM CST
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
ACRX: 6.61 (+0.06)
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BIRT: 6.60 (+0.02), ACRX: 6.61 (+0.06), AWR: 37.12 (+0.53), ACPW: 1.87 (+0.02), ADUS: 23.80 (-0.19)
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 6.61 (+0.06), XNCR: 16.83 (+0.77)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), INFI: 16.65 (+0.37), IG: 9.11 (-0.01)
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
ACRX: 6.61 (+0.06), CSCD: 14.28 (-0.21), BGFV: 14.46 (-0.12), BAH: 27.08 (-0.03), ACCO: 9.12 (+0.13)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), LJPC: 16.35 (-0.10), IG: 9.11 (-0.01)
Sedation - Pipeline Review, H1 2014
M2 - Thu Dec 11, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxkbln/sedation) has announced the addition of the "Sedation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - AcelRx Pharmaceuticals - Paion - Maruishi Pharmaceutical - NanoMedex Pharmaceuticals - Advicenne Pharma For more information visit http://www.researchandmarkets.com/research/fxkbln/sedation
ACRX: 6.61 (+0.06)
Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:31AM CST
AcelRx Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
PR Newswire - Tue Dec 02, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. Zalviso is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. AcelRx has partnered with the Grunenthal Group to commercialize Zalviso in the European Union and Australia. AcelRx had previously announced that in July 2014, Grunenthal had submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for Zalviso for the management of moderate to severe acute pain in adult patients in a medically supervised environment. Obtaining the CE Mark is an important step in the potential approval of the Zalviso MAA.
ACRX: 6.61 (+0.06)
Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 6.61 (+0.06), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), GSK: 42.85 (+0.11), SRNE: 9.50 (+0.99), NEPT: 1.88 (+0.03), CELG: 109.60 (+3.48)
EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX
GlobeNewswire - Fri Nov 21, 5:47PM CST
Rosen Law Firm, P.A. reminds purchasers of common stock and call options and sellers of put options of AcelRx Pharmaceuticals, Inc. (Nasdaq:ACRX) during the period from December 2, 2013 through September 25, 2014 of the important December 1, 2014 lead plaintiff deadline in the class action.
ACRX: 6.61 (+0.06)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX
GlobeNewswire - Thu Nov 20, 10:58AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRX's put options between December 2, 2013 and September 25, 2014. ACRX: 6.61 (+0.06)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
Business Wire - Thu Nov 20, 9:32AM CST
Law Offices of Howard G. Smith reminds investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(NASDAQ:ACRX) that those who purchased or otherwise acquired AcelRx's common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" , have until December 1, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events
PR Newswire - Thu Nov 20, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at Piper Jaffray, RBC, Guggenheim and Roth Healthcare Conferences. Details of the events are as follows:
ACRX: 6.61 (+0.06)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Nov 19, 8:42PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(NASDAQ: ACRX) common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 1, 2014 to seek appointment as lead plaintiff. ACRX: 6.61 (+0.06)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014
Business Wire - Mon Nov 17, 5:48PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRX's put options between December 2, 2013 and September 25, 2014. ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals Announces Zalviso(TM) Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting
PR Newswire - Thu Nov 13, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that a moderated poster presentation will be made at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 13th Annual Pain Medicine Meeting to be held November 13th to November 16th, 2014 at the Hyatt Regency in San Francisco, CA. The annual ASRA meeting is the foremost scientific and educational event on invasive and non-invasive targeted therapies in pain medicine and brings together over 900 national and international thought leaders. Pamela Palmer, M.D. Ph.D. will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold
at The Street - Wed Nov 12, 8:04AM CST
AcelRx Pharmaceuticals (ACRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
ACRX: 6.61 (+0.06)
AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
at The Street - Tue Nov 11, 11:00AM CST
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
ACRX: 6.61 (+0.06)
